Patents Assigned to Children's Medical Center Corporation
  • Patent number: 10443091
    Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: October 15, 2019
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • Publication number: 20190309373
    Abstract: The present invention provides assays, methods and systems for selecting an effective therapy for a subset of cancer patients having cancer cells with increased expression of BML and FANCI genes and/or having copy number increase in chromosome location 15q26 in the cancer cells and for treatment of such patients with the effective therapy of cancer patients based on the personalized cancer cell expression profile.
    Type: Application
    Filed: May 6, 2019
    Publication date: October 10, 2019
    Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC., THE TECHNICAL UNIVERSITY OF DENMARK
    Inventors: Zoltan I. Szallasi, Andrea L. Richardson, Nicolai J. Birkbak, Zhigang Wang
  • Publication number: 20190309297
    Abstract: Described herein are methods and compositions relating to the treatment of cancer, e.g., breast cancer, using, e.g., aptamer-siRNA chimera molecules.
    Type: Application
    Filed: May 10, 2019
    Publication date: October 10, 2019
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Judy LIEBERMAN, Adi GILBOA-GEFFEN, Lee Adam WHEELER
  • Patent number: 10435756
    Abstract: Described herein are novel malignancy associated gene signature biomarkers, and assays and methods thereof, to classify prognosis or malignant potential of a cancer and identify cancer-initiating cells. The malignancy associated gene signature biomarkers, assays and methods described herein provide, in part, new methodologies to screen for novel drugs for treating cancers and tumors, such as, for example, triple-negative breast tumors. Using the assays and methods described herein proteasome inhibitors, histone deacetylase inhibitors, and glycolysis inhibitors, were identified as being highly effective in altering gene expression signatures specifically in malignant or cancer-initiating cells.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: October 8, 2019
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Judy Lieberman, Fabio Petrocca
  • Publication number: 20190300941
    Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
    Type: Application
    Filed: May 14, 2019
    Publication date: October 3, 2019
    Applicants: Children's Medical Center Corporation, The United States of America, As Represented by the Secretary, Department of Health & Human Services
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • Publication number: 20190298795
    Abstract: Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae. The antigens may be used therapeutically or prophylactically.
    Type: Application
    Filed: September 17, 2018
    Publication date: October 3, 2019
    Applicants: Genocea Biosciences, Inc., Children's Medical Center Corporation
    Inventors: Todd Gierahn, Richard Malley
  • Publication number: 20190300869
    Abstract: Disclosed herein are modified Clostridial Botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial Botulinum serotype B, comprising one or more substitution mutations at positions corresponding 1248 or 1249 in serotype B, strain 1. Specific substitution mutations include I1248F, I1248Y, I1248H, I1248W, V1249W, V1249F, V1249Y, V1249H, I1248W/V1249F, I1248W/V1249Y, I1248W/V1249H, I1248F/V1249Y, I1248F/V1249H, I1248Y/V1249H, I1248F/V1249W, I1248Y/V1249W, I1248H/V1249W, I1248Y/V1249F, I1248H/V1249F, or I1248H/V1249Y. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.
    Type: Application
    Filed: June 8, 2017
    Publication date: October 3, 2019
    Applicant: Children's Medical Center Corporation
    Inventors: Min Dong, Sicai Zhang, Pau Stenmark
  • Publication number: 20190300885
    Abstract: Described herein is a LIN28-independent role of TUTases in oncogenesis. Provided herein are compositions and methods for treating cancer via inhibition of TUTases. TUTase depletion also sensitizes the cells to disruptions in RNA metabolism and/or protein metabolism. Thus, further provided herein are strategies of combination therapy, combining TUTase inhibitors, agents that disrupt RNA metabolism, and agents that disrupt protein metabolism, to treat cancer.
    Type: Application
    Filed: June 7, 2017
    Publication date: October 3, 2019
    Applicant: Children's Medical Center Corporation
    Inventors: George Q. Daley, Kaloyan Tsanov, Daniel S. Pearson
  • Publication number: 20190298248
    Abstract: An apparatus for generating a prediction that a patient will experience a seizure based on a blood volume signal is provided. The apparatus may include a blood volume sensor to sense the blood volume in a location of a patient's body. The apparatus may extract one or more features from the blood volume signal and determine if the feature has changed over time. The apparatus may generate a prediction of whether the patient will experience a seizure based on the determination of whether the feature changed over time.
    Type: Application
    Filed: October 18, 2018
    Publication date: October 3, 2019
    Applicant: Children's Medical Center Corporation
    Inventors: Tobias Loddenkemper, Michele Jackson, Fatemeh Mohammadpour Touserkani, Eleonora Tamilia, Christos Papadelis
  • Patent number: 10426735
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: October 1, 2019
    Assignees: Massachusetts Institute of Technology, The Children's Medical Center Corporation
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Publication number: 20190290728
    Abstract: Described herein are methods and compostions relating to breaking or inhibiting T cell exhaustion by increasing TMEM16F levels and/or activity. The methods and compositions can thereby further relate to treatment of viral infections or cancer, treatment of a chronic disease, vaccine administration, administering a CAR-T therapy, or increasing the number of T-bet+ T cells in a subject. In some embodiments, the methods relate to treatment of an autoimmune or inflammatory disease by inhibiting TMEM16F levels and/or activity.
    Type: Application
    Filed: October 20, 2017
    Publication date: September 26, 2019
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Florian WINAU, Yu HU
  • Publication number: 20190292239
    Abstract: Provided are chimeric VEGF-binding proteins and nucleic acids (e.g., a vector) encoding chimeric VEGF-binding proteins, methods and host cells for producing these proteins and nucleic acids, and pharmaceutical compositions containing these proteins and nucleic acids. Also provided are methods of treating an angiogenic disease or disorder that include administering at least one of the chimeric VEGF-binding proteins or at least one of the nucleic acids (e.g., a vector) encoding a chimeric VEGF-binding protein.
    Type: Application
    Filed: March 4, 2019
    Publication date: September 26, 2019
    Applicants: Children's Medical Center Corporation, The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: Bob Carter, Jeng-Shin Lee, Szofia S. Bullain, Richard C. Mulligan
  • Patent number: 10420645
    Abstract: A device for treating tricuspid regurgitation includes a shaft and a first fixation mechanism disposed on a distal end of the shaft. The first fixation mechanism is configured to anchor the device to a first cardiac tissue. The device includes a second fixation mechanism disposed on a proximal end of the shaft. The second fixation mechanism is configured to anchor the device to a second cardiac tissue. The device includes an approximation mechanism connecting the first fixation mechanism and the second fixation mechanism, wherein the approximation mechanism causes the second fixation mechanism to move along the shaft toward the first fixation mechanism to approximate the first cardiac tissue and the second cardiac tissue.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: September 24, 2019
    Assignees: Children's Medical Center Corporation, The Brigham and Women's Hospital, Inc.
    Inventors: Pedro J. Del Nido, Haruo Yamauchi, Nikolay V. Vasilyev, Maria Jose M. Nunes Pereira, Eoin D. O'Cearbhaill
  • Patent number: 10420742
    Abstract: Disclosed herein are compositions and methods for treating or preventing certain cancers in a subject. In certain embodiments such compositions and methods generally relate to the use of G-coupled protein receptor 40 (GPR40) agonists to inhibit the growth or induce apoptosis of certain cancer cells. The compositions and related methods disclosed herein may be used to treat subjects affected by cancers, such as melanoma, medullary thyroid carcinoma, malignant peripheral nerve sheath tumors and neuroblastoma, and to reduce the incidence of metastases in such affected subjects.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: September 24, 2019
    Assignee: The Children's Medical Center Corporation
    Inventors: Mark Puder, Deepika Nehra, Brian Kalish
  • Patent number: 10420778
    Abstract: The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA).
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: September 24, 2019
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Leonard I. Zon, Alison M. Taylor
  • Publication number: 20190284164
    Abstract: The instant invention provides photolysable compounds, and their use in reversible chemical induced dimerization and light-induced regulation of proteins.
    Type: Application
    Filed: August 20, 2018
    Publication date: September 19, 2019
    Applicants: Children's Medical Center Corporation, President and Fellows of Harvard College
    Inventors: Thomas L. Schwarz, Matthew R. Banghart, Amos Gutnick
  • Publication number: 20190270798
    Abstract: Disclosed are compositions and methods for modulating the activity of TGF-?. More particularly, compositions and methods for modulating the release of active TGF-? from an LRRC33-TGF-? prodomain-TGF? ternary complex are provided, as are and methods of treatment based upon such modulation.
    Type: Application
    Filed: October 25, 2017
    Publication date: September 5, 2019
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Timothy Alan SPRINGER, Chafen LU, Yan QIN, Aiping JIANG
  • Patent number: 10403007
    Abstract: System and method for processing magnetic resonance imaging (MRI) data of an object to perform motion correction. The method comprises estimating, for each slice of the MRI data, parameters for a state space model using a filter that predicts the location of the object for temporally adjacent slices, wherein the state space model represents motion dynamics of the object throughout acquisition of a three-dimensional volume, registering the slices to a reference image based, at least in part, on the estimated parameters, reconstructing an image based, at least in part, on the registered two-dimensional slices, and outputting the reconstructed image.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: September 3, 2019
    Assignee: Children's Medical Center Corporation
    Inventors: Ali Gholipour-Baboli, Bahram Marami, Simon K. Warfield, Benoit Scherrer, Onur Afacan
  • Publication number: 20190263785
    Abstract: Provided herein are bifunctional compounds that inhibit MALT1 and/or promote targeted ubiquitination for the degradation of MALT1. In particular, provided are compounds that can bind MALT1, a protein whose activity is responsible for constitutive NF-KB signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)), and can assist in its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon, VHL), which can ubiquitinate MALT1, marking it for proteasome degradation. Also provided are pharmaceutical compositions comprising the bifunctional compounds, methods of treating cancer with the bifunctional compounds, methods of promoting the degradation of MALT1, and methods of binding E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.
    Type: Application
    Filed: October 31, 2017
    Publication date: August 29, 2019
    Applicants: Cornell University, Dana-Farber Cancer Institute ,Inc., Children's Medical Center Corporation
    Inventors: Ari M. Melnick, Lorena Fontan Gabas, llkay Us, Gabriella Casalena, Nathanael S. Gray, David A. Scott, John Hatcher, Guangyan Du, Hao Wu, Qi Qiao
  • Publication number: 20190261596
    Abstract: A device for detecting and recording animal behavior is provided. The device includes at least one corral that defines a contained field, the base surface of the at least one corral being sensitive to the animal's footprint. The device also includes an image capturing device that cooperates with the base surface to capture both a profile of the animal's full footprint and a profile of the animal's toe print when the animal is standing on its toes. In some embodiments, the device is capable of providing a stimulus to the animal and observing the resulting behavior of the animal via the image capturing device.
    Type: Application
    Filed: February 14, 2019
    Publication date: August 29, 2019
    Applicants: Children's Medical Center Corporation, President and Fellows of Harvard College
    Inventors: Clifford J. Woolf, David P. Roberson, Alexander B. Wiltschko, Sandeep Robert Datta